
What is claimed:

1. A compound of formula I



I

wherein R is

$-P(O)(OH)_2$ or $-P(O)(OR_1)(OR_2)$;

R_1 is H, $-C_{1-26}$alkyl, aryl, C_{1-6}alkC(O)O-C_{1-26}alkyl, $-C_1$alkOC(O)C_{1-26}alkyl, or C_1alkOC(O)OC_{1-26}alkyl; and

R_2 is $-C_{1-26}$alkyl, aryl, C_{1-6}alkC(O)O-C_{1-26}alkyl, $-C_1$alkOC(O)C_{1-26}alkyl, or C_1alkOC(O)OC_{1-26}alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R is $-P(O)(OH)_2$.
3. The compound of claim 1, wherein R is $P(O)(OR_1)(OR_2)$.
4. The compound of claim 3, wherein R_1 is H.
5. The compound of claim 3, wherein R_1 is $-C_{1-26}$alkyl.
6. The compound of claim 3, wherein R_1 is aryl.
7. The compound of claim 3, wherein R_1 is C_{1-6}alkC(O)O-C_{1-26}alkyl.
8. The compound of claim 3, wherein R_1 is $-C_1$alkOC(O)C_{1-26}alkyl.
9. The compound of claim 3, wherein R_1 is C_1alkOC(O)OC_{1-26}alkyl.
10. The compound of any one of claims 4 to 9, wherein R_2 is $-C_{1-26}$alkyl, aryl.
11. The compound of any one of claims 4 to 9, wherein R_2 is C_{1-6}alkC(O)O-C_{1-26}alkyl.
12. The compound of any one of claims 4 to 9, wherein R_2 is $-C_1$alkOC(O)C_{1-26}alkyl.
13. The compound of any one of claims 4 to 9, wherein R_2 is C_1alkOC(O)OC_{1-26}alkyl.
14. The compound of any one of the preceding claims, in the form of a pharmaceutically acceptable salt.

15. A pharmaceutical composition comprising a compound of any one of the preceding claims, or a pharmaceutical salt thereof, and a pharmaceutically acceptable excipient.

16. Use of a compound of any one of claim 1 to 13 in the manufacture of a medicament for treating malignant hyperthermia, chronic spasticity, exertional heat stroke, cardiac arrhythmias, tachycardia, atrial fibrillation, cardiac arrest, myocardial infarction, heart failure, myocardial injury, cardiomyopathy, central core disease, amyotrophic lateral sclerosis, rhabdomyolysis, Duchenne muscular dystrophy, ataxia, detrusor overactivity, overactive bladder, seizure, epilepsy, neuroleptic malignant syndrome, human stress disorder, Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, ischemia-reperfusion injury, neuronal reperfusion injury, hypoxia, cerebral aneurysm, subarachnoid hemorrhage, stroke, hyperthermia associated with drug abuse, hyperthermia associated with drug overdose, nerve agent exposure, nerve gas exposure, or acetylcholine accumulation.

17. The use of claim 16, wherein the administration is intravenous administration.

18. The use of claim 16, wherein the administration is intramuscular administration.


19. The use of claim 16, wherein the administration is oral administration.

20. The use of claim 16, wherein the administration is subcutaneous.

21. The use of claim 16, wherein the administration is intranasal.

22. The use of claim 16, wherein the administration is intraosseous.


23. A compound of formula II-A



II-A


or a pharmaceutically acceptable salt thereof.

24. The compound of claim 24, wherein the compound of formula II-A is



.

25. Use of a compound of formula II-A



II-A

for treating malignant hyperthermia, chronic spasticity, exertional heat stroke, cardiac arrhythmias, tachycardia, atrial fibrillation, cardiac arrest, myocardial infarction, heart failure, myocardial injury, cardiomyopathy, central core disease, amyotrophic lateral sclerosis, rhabdomyolysis, Duchenne muscular dystrophy, ataxia, detrusor overactivity, overactive bladder, seizure, epilepsy, neuroleptic malignant syndrome, human stress disorder, Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, ischemia-reperfusion injury, neuronal reperfusion injury, hypoxia, cerebral aneurysm, subarachnoid hemorrhage, stroke, hyperthermia associated with drug abuse, hyperthermia associated with drug overdose, nerve agent exposure, nerve gas exposure, or acetylcholine accumulation.